HC Wainwright Has Bearish Forecast for Pharvaris Q1 Earnings

Pharvaris N.V. (NASDAQ:PHVS) – Equities research analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for Pharvaris in a research note issued on Monday, April 6th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.83) per share for the quarter, down from their prior estimate of ($0.80). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Pharvaris’ Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($1.04) EPS, FY2026 earnings at ($3.71) EPS, FY2027 earnings at ($2.91) EPS, FY2028 earnings at ($1.14) EPS and FY2029 earnings at $1.64 EPS.

A number of other equities analysts have also recently commented on PHVS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Sunday. Wedbush raised their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Royal Bank Of Canada lowered their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Pharvaris has an average rating of “Moderate Buy” and an average target price of $42.80.

Pharvaris Trading Down 1.9%

PHVS stock opened at $27.84 on Wednesday. The company has a market capitalization of $1.51 billion, a P/E ratio of -8.26 and a beta of -2.58. Pharvaris has a twelve month low of $11.51 and a twelve month high of $29.85. The business has a 50 day simple moving average of $27.08 and a 200-day simple moving average of $25.48.

Institutional Investors Weigh In On Pharvaris

Several hedge funds have recently modified their holdings of PHVS. GF Fund Management CO. LTD. acquired a new stake in shares of Pharvaris during the fourth quarter worth $35,000. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Pharvaris during the third quarter worth $75,000. Barclays PLC acquired a new stake in shares of Pharvaris during the fourth quarter worth $77,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Pharvaris during the fourth quarter worth $86,000.

Key Stories Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wedbush raised its price target to $42 and kept an “outperform” rating, implying roughly a 50% upside from current levels — a near-term bullish catalyst from an influential equity shop. Benzinga
• Positive Sentiment: HC Wainwright issued long-range FY2030 estimates calling for EPS of $5.37 and maintains a “Buy” rating with a $60 target — a highly constructive, bullish long-term projection that signals analysts expect strong eventual profitability. MarketBeat
• Neutral Sentiment: Brokerage consensus remains favorable overall — PHVS is reported to have an average rating of “Moderate Buy,” reflecting broad analyst support but varied views on timing and magnitude of upside. American Banking News
• Neutral Sentiment: Royal Bank of Canada trimmed its price target slightly from $52 to $51 but left an “outperform” rating in place — a small downgrade in projection that still implies large upside, so its market impact is muted. Benzinga
• Negative Sentiment: Coverage and commentary are questioning whether Phase 3 completion and projected 2025 losses change Pharvaris’ investment narrative; concerns about near-term profitability and how the market will value post‑Phase 3 commercialization are weighing on sentiment. Yahoo Finance

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.